Abstract

THE ROLE OF ANTI-MULLERIAN HORMONE IN THE EVALUATION OF THE EFFECTIVENESS OF METFORMIN HYDROCHLORIDE THERAPY IN POLYCYSTIC OVARIAN SYNDROME

Parahuleva N.*, Uchikova E., Orbecova M., Mihaylova A. and Parahuleva M.

ABSTRACT

Objectives: To evaluate the role of Anti-Mullerian hormone (AMH) in the evaluation of the effectiveness of short- (3 months) and long-term (6 months or more) Metformin hydrochloride therapy in women with polycystic ovarian syndrome (PCOS). Маterial and methods: Ninetyfive women between the age of 18 and 35, who were divided into two groups: a control group of 50 healthy women (n=50) and 45 women with polycystic ovarian syndrome(n=45) (PCOS), approximately at the age of 25,09 ±1.29 and BMI 27,21 ±0,79, were examined. Serum levels of AMH, LH, FSH, Tsestorenon, Androstendion, E2, Plasma glucose and IRI were examined. The individual values of HOMA-IRI and BMI were found out. Cases diagnosed with PCOS (n=45) were treated with Metformin hydrochloride. The dose during the treatment was 3х 850 mg, a total of 2550 mg daily dose for 6 months. The index measurements were made before starting the intake of Metformin hydrochloride (Т0), during the third month (Т3) and the sixth month (Т6) of the beginning of the treatment. Results: A positive correlation between the serum values of АМH and Аndrostendion (r=0,490), Теstosterone (r=0,427) and LH ( r= 0,431) and a negative correlation between АМH, FSH (r=-0,420) and Е2 (r=-0,588) were found. A significant difference between the initial level of АМH (T0-16,09ng/ml) and the level after the third month (T3-14,29ng/ml) р>0,05 was not found. The serum level of АМH – 3,5 ng/ml was decreased after the sixth month (T6-12,59ng/m)l compared to the first measurement (T0-16.09ng/ml) and the there was a significant difference: u=2,36, р

Keywords: Anti-Mullerian hormone, AMH, Metformin, Polycystic ovarian syndrome, PCOS.